Find Clinical Trial

An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer. – FINESSE


← Back
Study Phase

Phase 2

Therapeutic Area

Cancers

IndicationSolid tumors
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

LUCITANIB,
S080881

Active Substance CodeS080881
Protocol CodeCL2-80881-001
EudraCT Code2013-000288-10
NCT CodeNCT02053636


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility